Guardant Health insider plans to sell 8,571 shares

Guardant Health, Inc. (GH) insider Terilyn J. Monroe has filed a Form 144 indicating an intent to sell additional shares of company stock.

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) insider Terilyn J. Monroe has filed a Form 144 indicating an intent to sell additional shares of company stock. The filing covers 8,571 shares of common stock to be sold through Charles Schwab & Co., Inc. on or about 01/21/2026 on the NASDAQ, with an aggregate market value of 977902.00. These shares were acquired on 01/15/2026 via a restricted stock lapse as equity compensation from Guardant Health, Inc.

The filing also lists prior sales over the past three months. Monroe sold 55,167 shares of Guardant Health, Inc. on 12/01/2025 for gross proceeds of 5846164.00, and 10,031 shares on 01/07/2026 for gross proceeds of 1124200.00. Guardant Health, Inc. had 126,041,089 shares of common stock outstanding, providing context for the size of these transactions relative to the total share base.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Guardant Health (GH) shares does Terilyn J. Monroe plan to sell under this Form 144?

The Form 144 indicates an intent to sell 8,571 shares of Guardant Health, Inc. common stock, with an aggregate market value of 977902.00.

When are the new Guardant Health (GH) shares expected to be sold and on which exchange?

The filing lists an approximate sale date of 01/21/2026, with the 8,571 Guardant Health, Inc. common shares to be sold on the NASDAQ through Charles Schwab & Co., Inc.

How did Terilyn J. Monroe acquire the Guardant Health (GH) shares being sold?

The 8,571 Guardant Health, Inc. shares were acquired on 01/15/2026 through a restricted stock lapse from Guardant Health, Inc. as equity compensation.

What Guardant Health (GH) stock sales has Terilyn J. Monroe made in the past three months?

Over the past three months, Monroe sold 55,167 shares of Guardant Health, Inc. on 12/01/2025 for gross proceeds of 5846164.00, and 10,031 shares on 01/07/2026 for gross proceeds of 1124200.00.

How many Guardant Health (GH) shares are outstanding compared with this Form 144 sale?

The filing reports 126,041,089 Guardant Health, Inc. common shares outstanding, which serves as a baseline figure compared with the planned sale of 8,571 shares.

What does a Form 144 filing mean for Guardant Health (GH) investors?

A Form 144 shows a shareholder’s intent to sell restricted or control securities. This filing indicates Monroe’s planned sale of 8,571 Guardant Health, Inc. shares but does not itself execute the sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 04:10 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001652956
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Guardant Health, Inc.
SEC File Number	001-38683
Address of Issuer	3100 HANOVER STREET PALO ALTO CALIFORNIA 94304
Phone	855-698-8887
Name of Person for Whose Account the Securities are To Be Sold	Monroe Terilyn J.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	8571	977902.00	126041089	01/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/15/2026	Restricted Stock Lapse	Guardant Health, Inc.			8571	01/15/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Terilyn J. Monroe 3100 HANOVER STREET PALO ALTO CA 94304	Guardant Health, Inc.	12/01/2025	55167	5846164.00
Terilyn J. Monroe 3100 HANOVER STREET PALO ALTO CA 94304	Guardant Health, Inc.	01/07/2026	10031	1124200.00

144: Remarks and Signature

Remarks
Date of Notice	01/21/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/02/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Terilyn J. Monroe
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)